Effect of KCA-098, a new benzofuroquinoline derivative, on bone mineral metabolism
- Biol Pharm Bull. 1994 Apr;17(4):504-8. doi: 10.1248/bpb.17.504.
- 1. Central Research Laboratory, Kissei Pharmaceutical Co., Ltd., Nagano, Japan.
The effect of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoli ne-6-one designated as KCA-098) on the bone mineral metabolism of chick embryonic bone was examined. KCA-098 dose-dependently inhibited bone resorption of cultured chick embryonic femora and calvariae. It increased the length, dry weight, and calcium and phosphorus contents of 9-d-old chick embryonic femurs cultivated for 6 d, indicating that it stimulated bone formation. These results show that KCA-098 has the unique effects of inhibiting bone resorption and stimulating bone formation of chick embryo. In addition, in an in vivo experiment, oral administration of KCA-098 (3.0 mg/kg/d) for 16 weeks led to an increase in calcium and phosphorus content as well as an increase in the amount of force required to break the femur from ovariectomized rats, suggesting that it may be useful for the treatment of bone diseases.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Drug DerivativeResearch Areas: Metabolic Disease